Macrogenics (MGNX) Provides Update on Corporate Progress, TAMARACK Phase 2 Study Data, Q1 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. MU
5. USO
6. GOOGL
7. APGE
8. DFTX
9. NAVN
10. IBM

Go back to Macrogenics (MGNX) Provides Update on Corporate Progress, TAMARACK Phase 2 Study Data, Q1 Results

TD Cowen Downgrades MacroGenics (MGNX) to Hold

May 10, 2024 5:30 AM EDT

TD Cowen analyst Boris Peaker downgraded MacroGenics (NASDAQ: MGNX) from Buy to Hold.

The analyst comments "Efficacy was promising with 44% and 37% cPSA50s and 18% and 25% cORRs at 2.0mg and 2.7mg, respectively. However, safety deteriorated from the abstract which raises material questions.... More